New research published in the Journal of Leukocyte Biology suggests that adenosine deaminase enhances anti-HIV-1 specific immune responses by reducing the action of cells that impede HIV-specific defenses
03 February 2016 | Eurekalert Medicine & Health
CytoDyn Inc. today announced that its study of a passive-antibody monotherapy, PRO 140, which is given as a weekly injection, has shown complete viral-load suppression for well over a year with some patients approaching 17 months. The Company believes that complete virologic suppression through treatment with a single agent rather than through the widely used HAART combination therapy could present a significant opportunity to treat HIV patients. CytoDyn is currently conducting a pivotal Phase 3 trial for PRO 140 with expected commercialization in 2017.
27 January 2016 | Cytodyn Inc.
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected. The potency of the combination treatment, tested so far in mice, suggests that it would be possible to rid the body of HIV for months, reducing the frequency with which patients must take these medications from daily to several times a year.
27 January 2016 | National Institute of Mental Health
Given the success of currently available oral therapies -- in which essentially 100% of people who take it are virologically suppressed -- why do so many people say they want injectable shots instead?
21 January 2016 | TheBody Pro
ABX464 is a first-in-class orally available antiviral drug candidate for the treatment of patients with HIV infection. It blocks HIV replication through a unique mechanism of action that leads to the destruction of viral RNA. A dose-dependent increase in the response rate to ABX464 monotherapy was observed in the study. The majority of patients who received the highest dose (150 mg) showed a viral load reduction of at least 0.5 log (greater than 68% reduction) during the treatment period.
13 January 2016 | Medical News Today
Janssen Sciences Ireland UC (Janssen), formalized its collaboration with ViiV Healthcare on phase III development and commercialization of a two drug regimen of two long acting, all-injectable formulations of rilpivirine (a non-nucleoside reverse transcriptase inhibitor by Janssen) and cabotegravir (ViiV Healthcare).
08 January 2016 | Street Insider
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today.
24 December 2015 | National Institute of Allergy and Infectious Diseases (NIAID)
A new life cycle stage in HIV infection has been identified thanks to a novel technique they developed to take images of intact infected cells. Researchers have shown that this phase of infection, dubbed intra-nuclear migration, relies on the human protein CPSF6 to guide the virus through the host cell's nucleus and position it at active genes where it prefers to make its home.
19 December 2015 | Science Daily
Bristol-Myers Squibb Company today announced that it has entered into two individual agreements with ViiV Healthcare, a global HIV company, to divest its pipeline of investigational HIV medicines consisting of a number of programs at different stages of discovery, preclinical and clinical development. The agreements with ViiV Healthcare do not impact Bristol-Myers Squibb’s marketed HIV medicines, including Reyataz, Evotaz, Sustiva and Atripla. Bristol-Myers Squibb remains committed to the commercialization of these products and to those patients who rely on these medicines.
18 December 2015 | Bristol-Myers Squibb press release
Preliminary data suggest adenoviral delivery method superior for immune stimulation and control of viral load in the absence of antiretroviral therapy (ART); two of three subjects remain off ART for more than one year.
14 December 2015 | Sangamo Biosciences press release